Chemokine Receptor CCR5 Mediates AlloImmune Responses in Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 3, 2010, Pages 311-319

  Palmer, Lisa A ^a   Sale, George E ^b   Balogun, John I ^a   Li, Dan ^a   Jones, Dan ^a   Molldrem, Jeffrey J ^a   Storb, Rainer F ^b   Ma, Qing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

CCR5; CD4; CD8; Chemokine; GVHD

Indexed keywords

CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ALLOIMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE MARKER; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; LIP BIOPSY; LYMPHOCYTIC INFILTRATION; MIXED LYMPHOCYTE REACTION; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN BIOPSY; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION;

ANTIGENS, CD1; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DENDRITIC CELLS; GRAFT VS HOST DISEASE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; LANGERHANS CELLS; LEUKOCYTES, MONONUCLEAR; LIP; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; RECEPTORS, CCR5; SKIN; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 75749115630     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.12.002     Document Type: Article

References (39)

1. Appelbaum F.R. Haematopoietic cell transplantation as immunotherapy. Nature 411 (2001) 385-389
2. Sale G.E. The Pathology of Organ Transplantation (1990), Butterworth Publishers, Inc., London 229-260
3. Ferrara J.L.M., and Antin J.H. The pathophysiology of graft-versus-host disease. In: Thomas E.D., Blume K.G., and Forman S.J. (Eds). Hematopoietic Cell Transplantation (1994), Blackwell Scientific Publications, Boston, MA 305-315
4. Sale G.E. Does graft-versus-host disease attack epithelial stem cells?. Mol Med Today 2 (1996) 114-119
5. Fowler D.H., and Gress R.E. Graft-versus-host disease as a Th1-type process: regulation by donor cells of Th2 cytokine phenotype. In: Ferrara J.L.M., Deeg H.J., and Burakoff S.J. (Eds). Graft-vs.-Host Disease (1997), Marcel Dekker Inc., New York 479-500
6. Ferrara J.L. Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors. J Hematother Stem Cell Res 9 (2000) 299-306
7. Luther S.A., and Cyster J.G. Chemokines as regulators of T cell differentiation. Nat Immunol 2 (2001) 102-107
8. Moser B., and Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2 (2001) 123-128
9. Kunkel E.J., and Butcher E.C. Chemokines and the tissue-specific migration of lymphocytes. Immunity 16 (2002) 1-4
10. Garzino-Demo A., DeVico A.L., Conant K.E., and Gallo R.C. The role of chemokines in human immunodeficiency virus infection. Immunol Rev 177 (2000) 79-87
11. + T cells from a memory to memory/effector phenotype. J Immunol 168 (2002) 5538-5550
12. + T cells. J Immunol 168 (2002) 2225-2232
13. + T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest 104 (1999) 49-57
14. Serody J.S., Cook D.N., Kirby S.L., Reap E., Shea T.C., and Frelinger J.A. Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier. Blood 93 (1999) 43-50
15. + T cells to the liver, lung, and spleen during graft-versus-host disease. Blood 96 (2000) 2973-2980
16. Murai M., Yoneyama H., Ezaki T., et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 4 (2003) 154-160
17. Wysocki C.A., Burkett S.B., Panoskaltsis-Mortari A., et al. Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. J Immunol 173 (2004) 845-854
18. Panoskaltsis-Mortari A., Hermanson J.R., Taras E., Wangensteen O.D., Serody J.S., and Blazar B.R. Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 alpha (CCL3) after allogeneic BMT in mice. Blood 101 (2003) 3714-3721
19. Merad M., Hoffmann P., Ranheim E., et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 5 (2004) 510-517
20. Shimabukuro-Vornhagen A., Hallek M.J., Storb R.F., and von Bergwelt-Baildon M.S. The role of B Cells in the pathogenesis of graft-versus-host disease. Blood (2009) 2009 Sep 11 [Epub ahead of print]
21. Gros E., Bussmann C., Bieber T., Förster I., and Novak N. Expression of chemokines and chemokine receptors in lesional and nonlesional upper skin of patients with atopic dermatitis. J Allergy Clin Immunol 124 (2009) 753-760
22. + dermal dendritic cells: differential activation states suggest distinct functions. J Leukoc Biol 84 (2008) 143-151
23. Segerer S., Cui Y., Eitner F., et al. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis 37 (2001) 518-531
24. Fischereder M., Luckow B., Hocher B., et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 357 (2001) 1758-1761
25. Ma Q., Gooley T.A., and Storb R.F. CCR5 expression on cells from HLA-matched unrelated marrow donors and graft-versus-host disease. Biol Blood Marrow Transplant (2009). doi: 10.1016/j.bbmt.2009.05.003
26. Hansen J.A., Gooley T.A., Martin P.J., et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338 (1998) 962-968
27. Xing D., Decker W.K., Li S., et al. AML-loaded DC generate Th1-type cellular immune responses in vitro. Cytotherapy 8 (2006) 95-104
28. Martins S.L., St John L.S., Champlin R.E., et al. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 104 (2004) 3429-3436
29. Zlotnik A., and Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 12 (2000) 121-127
30. Sallusto F., Lenig D., Mackay C.R., and Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 187 (1998) 875-883
31. Chtanova T., and Mackay C.R. T cell effector subsets: extending the Th1/Th2 paradigm. Adv Immunol 78 (2001) 233-266
32. Jaksch M., Remberger M., and Mattsson J. Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 11 (2005) 280-287
33. Takahashi N., Sato N., Takahashi S., and Tojo A. Gene-expression profiles of peripheral blood mononuclear cell subpopulations in acute graft-vs-host disease following cord blood transplantation. Exp Hematol 36 (2008) 1760-1770
34. Bogunia-Kubik K., Duda D., Suchnicki K., and Lange A. CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica 91 (2006) 1628-1634
35. Gerard C., and Rollins B.J. Chemokines and disease. Nat Immunol 2 (2001) 108-115
36. Proudfoot A.E. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2 (2002) 106-115
37. De Clercq E. New anti-HIV agents and targets. Med Res Rev 22 (2002) 531-565
38. Horuk R. Development and evaluation of pharmacological agents targeting chemokine receptors. Methods 29 (2003) 369-375
39. Dhami H., Fritz C.E., Gankin B., et al. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies. J Clin Pharm Ther 34 (2009) 147-160